The possibilities of therapy of patients with metastatic colorectal cancer with <i>BRAF</i> V600E mutation. Clinical cases

Abstract

Mutation in the BRAF V600E gene in metastatic colorectal cancer (CRC) occurs in 510% of cases and is a significant problem due to the aggressive course and extremely unfavorable prognosis. In recent years, new treatment options for BRAF mutated CRC have been emerging, for example, combinations of BRAF inhibitors, anti-EGFR antibodies with optional addition of MEK inhibitors. The possibility of local treatment methods is also being discussed. Objective: to evaluate the effectiveness of triple targeted therapy in BRAF-mutated metastatic colorectal cancer. On the example of 2 clinical cases of long-term treatment of patients with this molecular subtype, possible treatment options are discussed.

Keywords

• metastatic colorectal cancer
• braf v600e mutation
• second-line therapy
• braf inhibitors
• encorafenib
• cetuximab
• beacon